Hyperion Therapeutics Inc (HPTX) 45.99 $HPTX Stratos

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Hyperion Therapeutics Inc (HPTX) 45.99 $HPTX

Stratos Group Adds Life Sciences Leader to Advisory Board
PR Newswire - Thu Nov 19, 2:21PM CST
Stratos Group today announced the addition of Chris Rivera to its Board as a Life Science Advisor.
HPTX: 45.99 (+0.02)

National Association of Professional Women Inducts Kamal Sigel, Vice President of Hyperion Therapeutics, Inc., Into its VIP Professional Woman of the Year Circle
PRWeb - Mon Aug 10, 11:01PM CDT
The National Association of Professional Women (NAPW) honors Kamal Sigel as a 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized with this prestigious distinction for leadership in business. NAPW is the nation's leading networking organization exclusively for professional women, boasting more than 700,000 members and over 200 operating Local Chapters.
HPTX: 45.99 (+0.02)

Hepatic Encephalopathy Therapeutics Pipeline Review, H1 2015 - 4 Companies & 5 Drug Profiles
M2 - Mon Jun 08, 10:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/std5dn/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Hyperion Therapeutics, Inc. - Ocera Therapeutics, Inc. - Umecrine Cognition AB Drug Profiles - CVXL-0060 - glycerol phenylbutyrate - ornithine phenylacetate - rifaximin - THDP-17 For more information visit http://www.researchandmarkets.com/research/std5dn/hepatic
OCRX: 2.57 (-0.03), HPTX: 45.99 (+0.02)

Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 2:08PM CDT
Jazz Pharmaceuticals (JAZZ) reported first-quarter 2015 earnings of $1.65 per share, substantially lower than the Zacks Consensus Estimate of $1.95.
JAZZ: 150.53 (-0.44), CNCE: 11.82 (+0.33), HPTX: 45.99 (+0.02)

ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 10:20AM CDT
ARIAD Pharmaceuticals (ARIA) reported a first-quarter 2015 loss of 28 cents per share, a penny wider than the Zacks Consensus Estimate of a loss of 27 cents.
VRX: 20.95 (+0.06), PFE: 36.90 (-0.41), ARIA: 9.68 (-0.03), HPTX: 45.99 (+0.02)

What's in Store for Horizon Pharma (HZNP) in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 07, 2:45PM CDT
Horizon Pharma (HZNP) is scheduled to report first-quarter 2015 results before the opening bell on May 8.
IPXL: 31.15 (-0.27), ACT: 298.98 (-2.94), HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma plc Completes Acquisition of Hyperion Therapeutics, Inc.
Marketwired - Thu May 07, 11:45AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has completed the acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX).
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma to acquire all outstanding common stock of Hyperion Therapeutics in tender offer at USD46.00 per share
M2 - Thu May 07, 3:06AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) on Thursday updated the results of its tender offer to acquire all of the outstanding shares of common stock of Hyperion Therapeutics (NASDAQ: HPTX) for USD46.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, if any.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma plc Announces Results of Tender Offer
Marketwired - Thu May 07, 1:45AM CDT
Horizon Pharma plc ("Horizon" (NASDAQ: HZNP) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Hyperion Therapeutics, Inc. ("Hyperion" (NASDAQ: HPTX) for $46.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, if any. The tender offer is being effected by Horizon's indirect subsidiary, Ghrian Acquisition Corp.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma plc Announces Waiver of Financing Proceeds Condition
Marketwired - Thu Apr 30, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that its affiliates, Horizon Pharma, Inc. ("Parent" and Ghrian Acquisition, Inc. ("Purchaser" , waived the "Financing Proceeds Condition" described in the Offer to Purchase in connection with the previously announced tender offer to acquire all of the outstanding shares of common stock of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) ("Hyperion" for $46.00 per share in cash, net to the seller in cash, without interest and less any applicable withholding taxes, if any. The tender offer is scheduled to expire at 12:01 a.m. (New York City time) on Thursday, May 7, 2015, unless further extended or earlier terminated. All other terms and conditions of the tender offer remain unchanged, including, without limitation, the "Minimum Condition" described in the Offer to Purchase.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma reports expiry of HSR Waiting Period for planned acquisition of Hyperion Therapeutics
M2 - Thu Apr 30, 3:07AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) reported on Wednesday the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR" with respect to its proposed acquisition of Hyperion Therapeutics (NasdaqGS:HPTX).
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma plc Announces Expiration of HSR Waiting Period for Proposed Hyperion Therapeutics, Inc. Acquisition
Marketwired - Wed Apr 29, 4:48PM CDT
Horizon Pharma plc (NASDAQ: HZNP) today announced the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR" expired effective Tuesday, April 28, 2015 with respect to its proposed acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX).
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes
Marketwired - Fri Apr 24, 3:05PM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary (the "Issuer" , has priced its offering of $475 million aggregate principal amount of 6.625% senior notes due 2023. The note offering is expected to close on or about April 29, 2015. The size of the offering was increased above the previously-announced size of $300 million aggregate principal amount of notes. As a result of the increased size of the note offering, Horizon Pharma, Inc. ("HPI" , the parent of the Issuer and a wholly-owned subsidiary of Horizon, expects that the aggregate principal amount of its previously-announced new term loan facility will be reduced from $500 million to $400 million.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion Therapeutics, Inc. Over the Proposed Sale of the Company to Horizon Pharma, Plc. - HPTX
BusinessWire - Mon Apr 20, 3:47PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion" or the "Company" (Nasdaq:HPTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Horizon Pharma, Plc. ("Horizon" (Nasdaq:HZNP) for approximately $1.1 billion. The Company's stockholders will receive $46 in cash for each share of Hyperion common stock they own.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and Intention to Enter Into New Term Loan Facility
Marketwired - Mon Apr 20, 6:23AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary (the "Issuer" , intends, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2023, and that Horizon Pharma, Inc., the parent of the Issuer and a wholly-owned subsidiary of Horizon ("HPI" , intends to enter into a new term loan facility in an aggregate principal amount of $500 million.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)

3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 10.98 (+0.12), AZN: 33.99 (+0.15), HZNP: 20.05 (+1.16), TEVA: 53.27 (-0.34), EGRX: 46.57 (+3.43), HPTX: 45.99 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 61

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 48

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 44

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 51

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 71

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 139

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytek Biosciences Prepares for Q2 2025 Financial Results Report

Updated Category News Views 214

Cytek Biosciences Plans Financial Disclosure for Second Quarter 2025 Cytek Biosciences, Inc. (NASDAQ: CTKB), based in Fremont, California, has dynamic news for stakeholders. The company is set to disclose its financial results for the second quarter of 2025 on August 6, 2025. This critical deadline follows the market closure that day, allowing for a comprehensive analysis...

Continue Reading
Alliance Trust PLC Shares Up: Latest NAV Per Share Insights

Updated Category News Views 171

Alliance Trust PLC Alliance Trust PLC's recent trading data dropped some key numbers that had traders buzzing. The Net Asset Value (NAV) per ordinary share hit the screens, giving everyone a fresh angle on how the company was really performing in a choppy market. NAV Breakdown: What's It Telling Us? Here's how the NAV shook out on the latest report: Valued on a Bid Price...

Continue Reading
Man Group Investment Insights: Spirent Communications and Trends

Updated Category News Views 199

Investment Insights from Man Group regarding Spirent Communications In today’s evolving market, understanding the dynamics between significant firms like Man Group PLC and Spirent Communications plc is vital for investors. This disclosure provides a snapshot of Man Group’s holdings and interests, particularly in relation to investing more than 1% in relevant...

Continue Reading
Sunny Lowe Joins Prime Mining Corp's Board of Directors

Updated Category News Views 221

Prime Mining Corp. (TSX: PRYM) (Other OTC: PRMNF) (Frankfurt: O4V3) has recently appointed Sunny Lowe to its Board of Directors. This announcement highlights a strategic move by the company to strengthen its leadership team as it continues its key projects, particularly the Los Reyes Project. Welcome to Sunny Lowe Murray John, Chair of the Board, expressed enthusiasm...

Continue Reading
Spotlight on Magnificent 7 Stocks: Opportunities in a Turbulent Market

Updated Category News Views 190

Market Overview: Understanding the Current Landscape The technology sector has seen major fluctuations recently, prompting discussions about the best investment opportunities. Economic uncertainties and market instability have resulted in significant stock losses, making this a pivotal moment for investors. The backdrop of Trump’s trade policies adds another layer of...

Continue Reading